Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach

Trial Profile

Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Dexmedetomidine (Primary)
  • Indications Hypertension; Surgical blood loss; Tachycardia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 02 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top